Renova Therapeutics Stock

renovatherapeutics.comBioTechFounded: 2009Funding to Date: $47.33MM

Renova Therapeutics is the developer of a portfolio of definitive gene and peptide therapies to restore health to people suffering from cardiovascular and metabolic diseases.

Register for Details

For more details on financing and valuation for Renova Therapeutics, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Enterprise Value (based on primary financings)

Enterprise Value

View Enterprise Value for Renova Therapeutics.

Register Today

Team

Management Team

Jack Reich Ph.D
Co-Founder, Chief Executive Officer & Board Member
Roy Cosan
Board Member & President
Catherine Bovenizer
Chief Financial Officer
Richard McCloskey MD
Executive Vice President, Clinical Development
Jennifer Spinella
Executive Vice President of Regulatory Affairs and Quality Assurance
Craig Andrews JD
Co-Founder, Board Member and Secretary

Board Members

Andy Noorda
Craig Andrews JD
Daniel Bradbury
Biobrit
Jack Reich Ph.D
Kirk Hammond MD
Michael Torres
Roy Cosan

Other companies like Renova Therapeutics in the BioTech sector

Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$1.3B
Sector
Last Round Est. Valuation
$3.1B
Sector
Last Round Est. Valuation
$5.81B
Sector
Last Round Est. Valuation
$1.2B
Sector
Last Round Est. Valuation
$1.6B
Sector
Last Round Est. Valuation
$1.61B

News

/PRNewswire-USNewswire/ -- Renova™ Therapeutics, a biopharmaceutical company developing gene therapy treatments for congestive heart failure and other chronic...